imatinib mesylate has been researched along with Cardiac Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Risha, SE; El-Sisi, AE; Hamed, MF; Ibrahim, HA; Sokkar, SS | 1 |
| Chen, GX; Fan, T; Hou, J; Liang, MY; Wang, LX; Wu, ZK; Yang, X; Yue, Y | 1 |
| Almeida, AG; Alves, D; David, C; Francisco, ARG; Guerra, L; Pinto, FJ | 1 |
| Baker, KS; Burke, MJ; Luo, X; Trotz, B; Verneris, MR; Wagner, JE; Weisdorf, DJ | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Etienne, G; Milpied, B; Nicolini, FE; Réa, D; Rigal-Huguet, F; Tulliez, M | 1 |
| Grossman, J; Hahn, BH; McMahon, M; Sahakian, L; Skaggs, BJ | 1 |
| Agee, S; Estis, J; Hasinoff, B; Herman, EH; Knapton, A; Lipshultz, S; Lu, QA; Rosen, E; Rosenzweig, B; Thompson, K; Todd, JA; Zhang, J | 1 |
| Jacob, S; Kovacs, RJ | 1 |
| Kio, EA; Lazarchick, J; Onitilo, AA; Singh, AK | 1 |
| Baumann, M; Duisters, RF; Heymans, S; Janssen, SH; Peutz-Kootstra, CJ; Pinto, YM; Schellings, MW; Schroen, B; van Leeuwen, RE | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Levi, A; Stefanizzi, C | 1 |
| Arai, A; Hayashi, S; Inazawa, J; Miura, O; Wakabayashi, S; Yan, W | 1 |
| Demetri, GD | 1 |
| Bankson, JA; Bornmann, W; Chen, J; Crespo, A; Fernández, A; Gelovani, J; Han, HD; Lin, Y; Lopez-Berestein, G; Ma, J; Mangala, LS; Ozturk, E; Peng, Z; Qin, C; Samarel, A; Sanguino, A; Shavrin, A; Sood, AK; Trent, J; Wulf, S | 1 |
| Stephenson, J | 1 |
1 review(s) available for imatinib mesylate and Cardiac Diseases
| Article | Year |
|---|---|
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Chromosomes, Human, Pair 4; Chronic Disease; Exons; Female; Furosemide; Glucocorticoids; Heart Diseases; Heart Ventricles; Hepatocytes; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Introns; Liver Diseases; Lymphocytes; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Necrosis; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Deletion; Sodium Potassium Chloride Symporter Inhibitors; Thrombosis | 2007 |
1 trial(s) available for imatinib mesylate and Cardiac Diseases
| Article | Year |
|---|---|
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
14 other study(ies) available for imatinib mesylate and Cardiac Diseases
| Article | Year |
|---|---|
Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cardiotoxicity; Caspase 3; Drug Carriers; Drug Compounding; Female; Heart Diseases; Humans; Imatinib Mesylate; Indoles; Ki-67 Antigen; MCF-7 Cells; Mice; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Tumor Burden | 2020 |
Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.
Topics: Animals; Cell Survival; Cells, Cultured; Echocardiography; Fibrosis; Gene Expression; Heart Diseases; Imatinib Mesylate; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Receptors, Platelet-Derived Growth Factor; Ventricular Remodeling | 2017 |
Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Topics: Aged; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Female; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Portugal; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Time Factors; Treatment Outcome | 2018 |
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Disease-Free Survival; Female; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; Erythropoietin; Fertility; Food-Drug Interactions; France; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Diseases; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2010 |
Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production.
Topics: Adult; Apolipoprotein A-I; Benzamides; Carotid Artery Diseases; Cell Line, Tumor; Cell Movement; Chemokine CCL2; Chemotaxis; Cholesterol; Clusterin; Female; Gene Expression; Heart Diseases; Humans; Imatinib Mesylate; Lipoproteins, HDL; Lupus Erythematosus, Systemic; Middle Aged; Molecular Mimicry; Monocytes; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2010 |
A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.
Topics: Animals; Apoptosis; Autophagy; Benzamides; Cardiotoxins; Heart Diseases; Imatinib Mesylate; Lysosomal-Associated Membrane Protein 2; Male; Muscle Cells; Myocardium; Oligonucleotide Array Sequence Analysis; Oxidation-Reduction; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Razoxane; Sarcomeres; Troponin; Weight Gain | 2011 |
Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate.
Topics: Adult; Benzamides; Echocardiography; Eosinophils; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Myocardial Contraction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thrombosis | 2005 |
Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Topics: Aortic Valve Insufficiency; Benzamides; Cardiomegaly; Chromosomes, Human, Pair 8; Cytogenetic Analysis; Heart Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Mitral Valve Insufficiency; Piperazines; Pyrimidines; Remission Induction; Trisomy | 2005 |
Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
Topics: Animals; Animals, Genetically Modified; Arterioles; Benzamides; Blood Pressure; Cells, Cultured; Fibrosis; Heart Diseases; Hemodynamics; Homozygote; Hypertension; Imatinib Mesylate; Kidney; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Myocardium; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Renin; Signal Transduction; Transcriptional Activation | 2006 |
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Topics: Animals; Benzamides; Cardiotoxins; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Heart Diseases; Humans; Imatinib Mesylate; K562 Cells; MAP Kinase Kinase 4; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Sprague-Dawley | 2007 |
New therapies show promise for patients with leukemia, hemophilia, and heart disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Genetic Therapy; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hemophilia A; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines | 2001 |